While patients with Crohn’s disease and ulcerative colitis are not considered immune-suppressed, special considerations must be taken when continuing therapies or beginning new medications during this pandemic.

Explore this module to learn how COVID-19 symptoms manifest in patients with inflammatory bowel disease (IBD) and hear how to safely treat this patient population.

Bite-sized content is presented in three formats — allowing you to engage with our experts and education on your own time:

• Enduring education.
• One-hour webinar featuring renowned experts.
• Roundtable discussion on AGA Community (AGA members only).

AGA Community Discussion

                     

Sign in to access [Member Only]

After you click the "Sign in to access" button, please click the "Launch" button on the top of this page to access the enduring material.

Course Director

Maria T. Abreu, MD, AGAF
Director, Crohn's & Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
University of Miami

Faculty

Peter D.R. Higgins, MD, PhD, MSc (CRDSA), AGAF (Moderator)
Professor, Division of Gastroenterology
Director, IBD Program
Director, Ambulatory and Chronic Disease Clinical Trial Support Unit
Department of Internal Medicine
University of Michigan

Marla Dubinsky, MD
Professor of Pediatrics and Medicine
Chief of Pediatric Gastroenterology and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Icahn School of Medicine, Mount Sinai NY

Corey A. Siegel, MD, MS
Professor of Medicine
Section Chief of Gastroenterology and Hepatology
Co-Director of the Inflammatory Bowel Disease (IBD) Center
Geisel School of Medicine, Dartmouth